Opioid dependence treatment and guidelines

Journal of Managed Care Pharmacy

Volumn 16, Issue 1 SUPPL. B, 2010, Pages

  Nicholls, Lance ^a   Bragaw, Lisa ^b   Ruetsch, Charles ^c  

^a Lancer Solutions LLC   (United States)

^b Shoreline Pharmaceutical Associates LLC   (United States)

^c Health Analytics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLONIDINE; CLOPIDOGREL; ERYTHROMYCIN; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; LEVACETYLMETHADOL; METHADONE; NALTREXONE; NEUROLEPTIC AGENT; NEVIRAPINE; OPIATE; PHENOBARBITAL; PHENYTOIN; RALOXIFENE; RIFAMPICIN; SAQUINAVIR; SEDATIVE AGENT; SERTRALINE; TICLOPIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; NARCOTIC ANALGESIC AGENT;

ANXIETY DISORDER; BEHAVIOR MODIFICATION; BRADYCARDIA; COMA; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; HEADACHE; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HUMAN; HYPOTENSION; INCIDENCE; LOW DRUG DOSE; MEDICAL SOCIETY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OPIATE ADDICTION; PATIENT COMPLIANCE; PATIENT COUNSELING; PRACTICE GUIDELINE; PRURITUS; PSYCHOSOCIAL CARE; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SUBSTITUTION THERAPY; TORSADE DES POINTES; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA; AMBULATORY CARE; ATTITUDE TO HEALTH; CLINICAL COMPETENCE; DRUG DEPENDENCE TREATMENT; HEALTH CARE DELIVERY; HEALTH PERSONNEL ATTITUDE; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ANALGESICS, OPIOID; ATTITUDE OF HEALTH PERSONNEL; CLINICAL COMPETENCE; COMBINED MODALITY THERAPY; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HUMANS; OFFICE VISITS; OPIOID-RELATED DISORDERS; PRACTICE GUIDELINES AS TOPIC; SUBSTANCE ABUSE TREATMENT CENTERS; TREATMENT OUTCOME;

EID: 77950504530     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.s1-b.14     Document Type: Review

References (31)

1. Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic noncancer pain. Pain Physician. 2006;9(1):1-39. Available at: http://www.painphysicianjournal.com/2006/january/2006;9;1-40.pdf. Accessed January 24, 2010.
2. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic noncancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) guidelines. Pain Physician. 2008;11(2 Suppl):S5-S62. Available at: http://www.painphysicianjournal.com/2008/march/2008;11;S5-S62.pdf. Accessed January 20, 2010. (Pubitemid 351682078)
3. DHHS. Substance Abuse and Mental Health Services Administration. Center for Substance Abuse Treatment. Detoxification and substance abuse treatment training manual-based on a treatment improvement protocol (TIP) Series 45. DHHS Publication No. (SMA) 08-4331. 2008. Available at: http://www.kap.samhsa.gov/ products/trainingcurriculums/pdfs/tip45-curriculum.pdf. Accessed January 25, 2010.
4. Fiellin DA, O'Connor PG. Office-based treatment of opioid-dependent patients. New Eng J Med. 2002;347(11):817-23. Available at: http://content.nejm. org/cgi/reprint/347/11/817.pdf. Accessed January 23, 2010.
5. Lexi-Comp (Lexi-Drugs, comp + specialties) [computer program]. Lexi-Comp; July 2, 2009.
6. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders, 2nd ed. 2006. Available at: http://www.psych.org. Accessed January 19, 2010.
7. Collins ED, Kleber HD, Whittington RA, et al. Anesthesia-assisted vs. buprenorphine or clonidine-assisted heroin detoxification and naltrexone induction a randomized trial. JAMA. 2005;294(8):903-13. Available at: http://jama.ama-assn.org.lp.hscl.ufl.edu/cgi/reprint/294/8/903. Accessed January 24, 2010.
8. Magellan Health Services. Introduction to Magellan's adopted clinical practice guidelines for the assessment and treatment of patients with substance use disorders. December 2008. Available at: http://www.magellanprovider.com/MHS/ MGL/providing-care/clinical-guidelines/clin-prac-guidelines/substance-abuse.pdf. Accessed January 26, 2010.
9. Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA clinical trials network field experience. Am J Addict. 2004(Suppl 1):S42-S66. (Pubitemid 38585690)
10. Gouldin WM, Kennedy DT, Small RE. American Pain Society. Methadone: History and recommendations for use in analgesia. APS Bulletin. 2000;10(5). Available at:. http://www.ampainsoc.org/pub/bulletin/sep00/updal.htm. Accessed January 24, 2010.
11. Suboxone (buprenorphine HCl and naloxone HCl dihydrate sublingual tablets) prescribing information. September 2006. Reckitt Benckiser Pharmaceuticals, Inc. Available at: http://www.suboxone.com/hcp/pi/. Accessed January 26, 2010.
12. Anonymous. The history of methadone. Available at: http://www.drugtext. org/library/books/methandbook/history.htm. Accessed January 26, 2010.
13. Helm S, Trescot AM, Colson J, et al. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008;11(2):225-35. Available at: http://www. painphysicianjournal.com/2008/march/2008;11;225-235.pdf. Accessed January 24, 2010. (Pubitemid 351546233)
14. Dolophine hydrochloride (Methadone hydrochloride tablets) prescribing information. October 2006. Roxane Laboratories, Inc. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM142842.pdf. Accessed January 24, 2010.
15. American Chronic Pain Association. ACPA chronic pain medications supplement 2008. Available at: http://www.theacpa.org/documents/ ACPA%20Chronic%20Pain%20Medications%20Supplement%202008.pdf. Accessed January 24, 2010.
16. Ancherson K, Clausen T, Gossop M, et al. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009;104(6):993-999
17. DHHS. Substance Abuse and Mental Health Services Administration. Center for Substance Abuse Treatment. Drug addiction treatment act of 2000 (DATA 2000). Title XXXV, Section 3502. Available at: http://buprenorphine.samhsa.gov/ titlexxxv.html. Accessed January 19, 2010.
18. DHHS. Substance Abuse and Mental Health Services Administration. Center for Substance Abuse Treatment. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. 2004. Available at: http://www.ncbi.nlm.nih. gov/bookshelf/br.fcgi?book=hssamhsatip&part=A72248. Accessed January 24, 2010.
19. Donaher PA, Welsh C. Managing opioid addiction with buprenorphine. Am Fam Physician. 2006;73(9):1573-1578
20. National Institute on Drug Abuse. Drugs, brains, and behavior: the science of addiction. NIH Publication # 07-5605. Reprinted February 2008. Available at: http://www.nida.nih.gov/scienceofaddiction/sciofaddiction.pdf. Accessed January 26, 2010.
21. Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290-97. Available at: http://content.nejm.org/cgi/reprint/343/18/ 1290.pdf. Accessed February 2, 2010.
22. Mattick RP, Ali R, White J, et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;98(4):441-452 (Pubitemid 36458126)
23. American Academy of Family Physicians. Strength of recommendation taxonomy (SORT). Available at: http://www.aafp.org/online/etc/medialib/aafp-org/ documents/news-pubs/afp/afpsort.par.0001.File/dat/sortdef07.pdf. Accessed January 24, 2010.
24. Glabman M. Multiple therapies help curb opioid dependence. Manag Care. 2009;1(1):14-20. Available at: http://www.managedcaremag.com/supplements/0812- opioids-workplace/opioids-in-the-workplace.pdf. Accessed January 19, 2010.
25. Kakko J, Grönbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry. 2007;164(5):797-803. Available at: http://ajp.psychiatryonline.org/cgi/reprint/ 164/5/797. Accessed January 24, 2010. (Pubitemid 46808535)
26. Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005;62(10):1157-1164
27. Schwartz RP, Highfield DA, Jaffe JH, et al. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006;63(1):102-109
28. Kaur AD, McQueen A, Jan S. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use. J Manag Care Pharm. 2008;14(2):186-94. Available at: http://www.amcp.org/data/jmcp/JMCPMaga-March%2008-186-194.pdf. (Pubitemid 351447682)
29. Caldiero RM, Parran TV, Adelman CL, et al. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved? Am J Addict. 2006;15(1):1-7.
30. Jones ES, Moore BA, Sindelar JL, et al. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009,99(1-3):132-140
31. Doran CM. Economic evaluation of interventions to treat opiate dependence: a review of the evidence. Pharmacoeconomics. 2008;26(5):371-393